Evaluation of Safety and Efficacy of Using Venus Freeze™ (MP)2 V2 System for Wrinkles Rhytides and Cellulite Treatment

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Venus Concept
Information provided by (Responsible Party):
Prof. Eli Shprecher, Venus Concept
ClinicalTrials.gov Identifier:
First received: November 3, 2010
Last updated: December 4, 2013
Last verified: December 2013

Skin aging is a multifactorial process involving the 3 layers of the skin: Epidermis, dermis and hypodermis.

Radio-frequency (RF) devices have been used for many years for a variety of surgical applications. The energy delivery systems of these established monopolar devices used a 'conductive coupling' delivery system in which energy is concentrated at the periphery of the electrode.

Venus Concept has developed the Venus Freeze™ system for wrinkles, rhytides and cellulite treatment. While treating wrinkles rhytides and cellulite, the treatment creates enough thermal effect to induce collagen remodeling with no ablative thermal damage in the epidermis or dermis.

Condition Intervention
Wrinkled Structure
Device: Venus Freeze™ system

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of Safety and Efficacy of Using Venus Freeze™ (MP)2 V2 System for Wrinkles Rhytides and Cellulite Treatment - a Pilot Study

Resource links provided by NLM:

Further study details as provided by Venus Concept:

Primary Outcome Measures:
  • To evaluate the safety of the Venus system for wrinkles and rhytides treatment. [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
    Number of Participants with Adverse Events

Secondary Outcome Measures:
  • To evaluate the efficacy of the Venus Freeze™ system for wrinkles and rhytides treatment. [ Time Frame: 5 months ] [ Designated as safety issue: No ]
    Number of Participants that shows at least one degree improvement of skin elastosis according to Fitzpatrick Scale following treatment with Venus Freeze™ System.

Estimated Enrollment: 60
Study Start Date: December 2010
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treament group
Venus Freeze (MP)2 V2 system treatments
Device: Venus Freeze™ system
10 RF treatments for wrinkles rhytides and cellulitis reduction by Venus Freeze System
No Intervention: control
control, no intervention


Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy males and females age 30 and up
  • Subjects with Fitzpatrick 4 to 9 degrees of elastosis
  • Subject able to comprehend and give informed consent for participation in this study
  • Subject must commit to all treatments and follow-up visits
  • Subject must sign the Informed Consent Form

Exclusion Criteria:

  • Subjects with implanted pacemakers, arrhythmias or any other severe known heart disorder
  • Subjects with any implantable metal device in the treatment area
  • Subjects on any medication that would affect the characteristic of the skin (medical or hormonal), such as "Accutane", within the past 6 months or photosensitizing medications
  • Subjects that have had any other invasive or non invasive method of skin therapy or hair removal performed in the past 9 months (in the treated area) Subjects who are scheduled or planned for any other invasive or non invasive method of skin therapy or hair removal in the treated area at the period of the study
  • Subjects who have any form of malignant skin cancer on the treatment area
  • Subjects with history of keloid formations or hypertrophic scarring
  • Pregnant or lactating Subjects
  • Subjects with Epilepsy or severe migraines
  • Subjects with permanent makeup/ tattoo/ body piercing (in the treated area)
  • Subjects with any Infection / abscess / dermatitis/ pains in treatment target area.
  • Subjects who suffer from autoimmune disorders or diabetes
  • Subjects with clotting disorders
  • Subjects are suffering from psychiatric disorders and treated with psychiatric medications.
  • Subject is suffering extreme general weakness.
  • Subject objects to the study protocol
  • Concurrent participation in any other clinical study
  • Physician objection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01234259

Contact: Hanna Levy, Dr. (972)-4-638-8837 hanna@qsitemed.com

Sourasky medical Centre Recruiting
Tel-Aviv, Israel, 64239
Contact: Hanna Levy, Dr.    (972)-4-638-8837    hanna@qsitemed.com   
Sponsors and Collaborators
Venus Concept
Principal Investigator: Eli Sprecher, Prof. Tel-Aviv Sourasky medical Centre, Israel
  More Information

No publications provided

Responsible Party: Prof. Eli Shprecher, Study principal investigator, Venus Concept
ClinicalTrials.gov Identifier: NCT01234259     History of Changes
Other Study ID Numbers: VN-WR- 01
Study First Received: November 3, 2010
Last Updated: December 4, 2013
Health Authority: Israel: Ethics Commission

Keywords provided by Venus Concept:

Additional relevant MeSH terms:
Connective Tissue Diseases
Pathologic Processes
Skin Diseases, Infectious

ClinicalTrials.gov processed this record on May 21, 2015